Biomarin Pharmaceutical Inc Investor Event Transcript, Nov 16, 2026
Biomarin Pharmaceutical Inc (BMRN)
Biomarin said revenue rose 60% since 2023, supported by rare-disease commercialization and a pipeline approaching major clinical catalysts. AI summary
Conference Transcript - BMRN 2026-11-16
Jun Li, Analyst — UBS
Thank you for joining our UBS global biopharma conference. My name is Jun Li, one of the biotech analysts at UBS. Here to kick us off is Alexander Hardy, CEO of Biomaren and Brian from the CFO of Biomaren. Alexander, thank you so much for spending time with us this morning. For the audience who may be new to the story, tell us who Biomaren is today. What have you delivered over the last three years since you joined? Why did you join? And why should investors be excited about what's ahead?
Alexander Hardy, CEO
Well, June, thanks very much for having us, and thanks, everybody, for joining for this conversation. That's a lot of questions, but let me just, let me, you know, I suppose, start off with, you know, where are we in our journey? So I've been at Biomarin for three years. We've done a lot of stuff, and during that time, I came to Biomarin because I saw the potential to create an iconic biotech company focused on rare diseases. There are also other large biotech companies, but they are not focused on rare diseases, and there are also midsize. Rare disease companies, but they're part of, you know, larger enterprises. And I saw all the building blocks, and I am convinced that we're on the path to do that. You know, the company over 25 years has built a set of capabilities all the way through from research. Development, regulatory, manufacturing, commercialization, focused on rare diseases, an 80-country footprint, which is really amazing. And that's what you need if you're in rare diseases, because you have to go to where the prevalent patient populations are. And in many cases, in many of these diseases, the largest patient potential is outside Europe and the United States. And we have that capability to reach them. We now have nine products. Six of them are first and disease treatments. I mean, nine products is really an incredible base. And what we've been doing over the last three years is really getting the company operating at scale to create that leadership position. We've dramatically improved the financial performance of the company. So since 2023, we've increased revenue by 60%. Between 2023 and 2025, we've increased earnings per share, doubled it, and cash flow by five times. That financial strength has allowed us to really build a really compelling balance sheet, and we've done a lot of transactions. So we got Gallifold and Pombility and Opfolder from the Amicus acquisition. And in addition, we've done, you know, four other pipeline deals that have given us assets all the way through from phase three to phase two to early research. And we're now at the stage in 27 where we start to see a bunch of really exciting clinical catalysts. So we have BMN333, our long-acting CNP. We have first patient data next year. No doubt we're going to talk about that. We have BMN 440 for HPP. We have the first patient data for that. That's a very, very large potential drug. And then we have, in front of the FDA, we have potentially our seventh first-in-disease treatment, which is Voxogo for hypochondroplasia, with a pidufidate in May. So you can see that, you know, we've got a fully formed, at-scale, Rare disease company here, and we've got an exciting growth trajectory, strong financial performance, and now an exciting pipeline as well.
Jun Li, Analyst — UBS
Excellent. Thanks for...
Alexander Hardy, CEO
I think I answered all your questions, but I could be wrong.
Jun Li, Analyst — UBS
We'll dig into it. Okay, good, good. We'll start with the Gallifold and POMOP. 3Q was the first full quarter since you acquired Amicus, and both products are performing well. What gets each product to the peak revenues that you laid out in August?
Alexander Hardy, CEO
Yeah. Shall I go ahead? I'll go ahead. So, you know, we set out, I mean, you know, the Amicus acquisition was really a compelling acquisition. It's basically Amicus was a smaller scale version of Biomarin, but we had more scale, more capabilities, and the ability to really maximize these two assets. Gallifold and Pombility Upfolder. And we have communicated in the second quarter earnings, we communicated what in our hands we believe the potential of these products could be. So Gallifold, we believe we can achieve a peak sales of 1.4 billion and Pombility and Upfolder 1.2 billion. And that's because we have that global footprint at a greater scale than Amicus had, and we have a depth of capabilities and the ability to invest to be able to achieve a faster peak. And a faster ramp and a higher peak. So with Gallifold, we believe the opportunity is particularly on the diagnosis side. There are a lot of patients who, with the disease of Fabre, that are not diagnosed. We think treatment rates can also be increased. We think Gallifold is very well positioned there. In the third quarter, we just announced, you know, 13% increase in number of patients treated, which is the first. A quarter in our hands versus a prior year under amicus control. That's a really nice, you know, level of growth. And we're also going to, of course, expand the number of countries as well. So we're planning to launch in another 10 countries. Right now, that's our plan. So then Pombility and OpFolder, the opportunity there really is the increase in the switch rate. And, um, It's well-positioned there with the evidence, the differentiation. We just, in October, released the Propel data, which is the five-year data. All really shows the benefits of switching from the existing ERTs to Pombility and Upfolder, and we grew patients on therapy in the third quarter by 69 percent. So I think you can already see that we're on a different trajectory, and we're confident in our ability to achieve those higher peak sales. That translates to about 40% higher peak for Gallifold and 20% higher peak than Pombility and Uppolder than Amicus would have achieved.
Jun Li, Analyst — UBS
Are there any upsides to your base case that you just laid out? You know, again, what would be, what would tell you as we track your progress that you will actually achieve that or exceed that possible?
Alexander Hardy, CEO
Yeah. Well, I think Gallifold, to go back to the propositions for each product where we think the biggest growth opportunity is, Gallifold, it's really that ability to increase the diagnosis rate. So in estimating those peak sales in our hounds, we didn't play with the top of the funnel. So we're not assuming the prevalence rate changes. There is a reasonable possibility, and we're going to certainly look at that. You know, that's one of the capabilities we have is looking at genotype to phenotype and increasing the understanding of the genetic mutations that are driving the disease. But really, we think that in our hands, Gallifold, we can increase the diagnosis rate. So watch the diagnosis rate. And, you know, these are things like family cascade screening, newborn screening. These are the sorts of things that Biomarin does really, really well. So newborn screening is working with governments in most cases to implement systematic newborn screening. So that you reduce that level of the diagnostic journey. The typical Fabray patient interacts with 10 different medical specialties before they receive a definitive diagnosis. So the opportunity is to shrink that down considerably, and that's the work we're doing. With Pombility in our folder, it's really about that switch rate, so gaining share. You know, here we are in Europe. There are four countries in Europe where we've already achieved number one market status. So we're the number one most prescribed Pompei drug. So that shows what's possible, and watch that as we do that in more and more markets, propelled by the real-world data and the physician experience.
Jun Li, Analyst — UBS
Great. So, Brian, you know, how is the Amicus integration progressing on both the synergies and accretion?
Brian Mueller, CFO
Yeah, thanks, June. It's a great question. The revenue opportunity that Alexander described is significant, but the Amicus synergized business, once we, you know, fully integrate the companies, really brings substantial earnings and cash flow potential as well. So let me take it three ways briefly. The strategic rationale, the operational design and plan, and now execution. So strategic rationale, as Alexander mentioned, you know, two rare disease assets on the strong part of their commercial revenue growth curve, but operating within what was a smaller scale company. So the promise of bringing these assets that fit hand in glove within Biomarin. On to the BioMarin platform, where we are already at scale, you know, not just the 80-country footprint, but all of the capabilities that it takes to commercialize and support these rare disease assets, the promise of a strong combined financial profile was strong from the beginning. Next was the planning and delivery. Once we dug in post-close and designed the integration plan, again, the model that we were striving for was not just merging two public companies, but how do we bring these two medicines onto the BioMarin operating platform? We designed a plan that called for... Taking out just about over half of the Amicus operating cost base. So out of about 430 million of non-GAAP operating expenses in calendar 25, we think we can achieve 220 million of synergies. The integration continues, you know, the rest of this year into next year. That's why we reference full year. 2028 is the first full year that we will realize the synergies. But again, the combined revenue, growing revenue plus synergized cost profile, we think we can run the combined, we think we can run the amicus business at about a 60% operating margin by the end of the decade. Then the last element is delivery and execution. We've pulled forward some of our targets now twice since we've started the integration. First was our deleveraging target. Originally, we planned to reduce our leverage to two and a half times EBITDA within two years of the acquisition. In the second quarter, we announced that we think we can do that almost a full year earlier, middle of next year. And then just in the last Q3 call, we announced that instead of being accretive in the first calendar year post-closing, we think the transaction will be accretive in the first nine months. So the teams are doing great. This is a top priority. Of course, there's some complicated, longer lead time integration items that we'll go into next year, but the teams are executing well, and we're delivering on the value.
Jun Li, Analyst — UBS
It's a real turnaround. You know, your base business, the metabolic conditions franchise grew by 44%. What makes this base business, this franchise durable, and what strategies will you leverage to continue to grow this very important?
Alexander Hardy, CEO
Yeah, so the metabolic conditions business unit, so part of our restructuring of Biomarin, we moved into a business unit structure. I mean, when you've got this many products, It's how you manage to attain focus and achieve the potential that the individual products So in our metabolic conditions business unit, that's where Pombility and Opfolder and Gallifold went into. But I think it is one of the things that's underappreciated by investors is actually the growth potential of products which are sort of legacy BioMarin products. So, you know, the products are in that business unit, apart from the two new Amicus products, Alderazyme, Naglazyme, Vimazim, and Brenura. These four products, we continue to grow. The third quarter, all of our Biomarin products added patients around the world. Even though these products, I mean, I'll just take, you know, Naglazyme and Alderazyme. These are long past their primary patent expiries. And we're still finding patients around the world. We're still launching them in that 80 country footprint. There are still countries where, you know, the regulatory path or the reimbursement path opens. And what we said, you know, in 2024 is we believe that these products, this is before the Amicus acquisition could grow at a high single digit growth rate. Into the long run. And, you know, it is pretty cool to see. And it's these capabilities of finding patients. There's still a lot of opportunity to grow for these products.
Jun Li, Analyst — UBS
What I find impressive about Byron Marin, and quite different from other companies that it covers, is your global footprint. How hard has it been to establish that global footprint? You've been doing this for 20 years. I mean, what does that look like from start to finish, establishing your presence in some country that other companies wouldn't dare go into?
Alexander Hardy, CEO
Yeah, yeah. It is something really remarkable for a mid-sized company to have this sort of global footprint. And in most of those countries, most of those 80 countries, these are by marine teams on the ground. I mean, other biotech companies will talk about, you know, our global footprint, but it's generally a distributor model. But we believe in rare disease, it's feasible and actually important in many cases to have your own people on the ground. This allows you to share learnings and experience between countries much more effectively. And nobody cares as much as we do about the successful products as opposed to a distributor who will have, obviously, multiple different companies' products within their portfolio. So, yeah, it's a source of real pride, but it is also a capability expertise. Rare disease is different, and rare disease in every country is different. So it's one thing to get the regulatory approval, and that represents its own set of challenges, but then the reimbursement and the access, which is totally feasible. Again, 80 countries, we have access. These are paid for by the government, by the public health care system in the vast majority of these markets. These aren't cash pay. But you obviously have a very individualized reimbursement. Often, in some cases, it's named patient reimbursement. And you really need to understand the system and have the relationships and the expertise and the reputation to be able to do that.
Jun Li, Analyst — UBS
Yeah, no, the feedback from the advocates' acquisition was very positive. So kudos to you guys for pulling that trigger at the right time. Perfect timing, by the way, with the patent extension. So, you know, let's move on to VoxSogo because it is an important product. It takes up a disproportionate amount of attention among the investors, but it is generating a billion-plus in revenue in achondroplasia, and you expect it to continue to grow in 2027 despite the competition from UVVal. So what are the levers for continued growth into next year and beyond?
Alexander Hardy, CEO
Well, there's actually three really important levels for VoxoGo, and the basis of it continuing to grow in 2027. One is the label. So for several more years, we'll be the only ones with the infant indication, the 0 to 2 or 0 to 3, depending on the competitor population. And why is this important is this is because this is where the incident population, the majority of our new patients starts on VoxoGo, And this has been the case for a little while now, in the infant population, all the guidelines, the international guidelines say diagnose and treat in achondroplasia as soon as possible after birth. And for example, in the U.S., 60 percent. of babies are actually now diagnosed in utero, and often the treatment decision is made before the baby is even born. So again, we're going to be, for the next several years, the only company with that indication. So it means new patient starts and the majority will be coming to Voxoga. Second is the global footprint we talked about. You know, important again, and it's fun to be out of the U.S. and talk about this and really resonate where so many companies and so many disease areas are so U.S. focused. You know, in achondroplasia, 68%, almost 70% of patients are outside the United States, Europe, Canada, and Australia. Almost 70% of patients. So we, again, coming back to that global footprint, we're going to continue to grow in that footprint. I mean, it's really remarkable. In the third quarter, we grew patients on Voxogo globally, despite competition in the United States, by 17% in the quarter. There's a lot more growth globally. We're still launching in countries. We're still penetrating in countries. There's a lot of growth there. And then the third thing I've already mentioned, which is really exciting, is new indication. So hypochondroplasia. Fidufa date at the end of May in the United States. We'll also, hopefully, next year have approvals in Europe and in other important countries around the world. So that will be the third sort of pillar of growth for Vox Ogo in 27. So it's going to be an exciting year for Vox Ogo.
Jun Li, Analyst — UBS
So, hypochondriplasia is an exciting new expansion opportunity. Tell us, like, how big is that market, and how many patients have you been able to identify so far that might be candidates for this once it's approved? Yeah, yeah.
Alexander Hardy, CEO
I mean, anytime you have a first-in-disease treatment, it's very, very exciting, and this is no different in rare disease than other therapy areas. When you have a first-in-disease treatment, you suddenly see the disease area opening up, and physicians and patients have a motivation to get diagnosis and discuss options. So, we believe that the genetic prevalence is very similar to achondroplasia globally. So, about 24,000 patients, but of those, you know, the diagnosis rate is the biggest issue. Again, there's been no approved treatment option. So, we guide people to think about a total addressable patient population of about 14,000 patients globally. And the work that we're doing right now is to increase that diagnosis rate. We've been able to increase that quite significantly so far. Again, when you have the phase three data, that's an important first milestone. Heads go up, people start to think about it. Now we have Bidu for Date, and our teams are out there in medical affairs doing disease awareness, increasing the diagnosis rate, and identifying a ready patient pool that, when the drug is approved, can be candidates for therapy and prosecuted by the sales force. So that's the work that's ahead of us. And there's a lot of excitement. The obvious advantage that we have is that this is the same treating physician group as achondroplasia. So they already know Voxogo. They're already comfortable with the safety and efficacy of Voxogo. So we don't have to build it. From scratch, like we did with achondroplasia, where there was no single treating or primary treating specialty. The pediatric endocrinologists, which we've reached about 1,200 now in the US and done the disease awareness, are either going to be the same audience. The other thing that's really cool about it is that the data looks really, really good. I mean, this is on the high end of the scenarios that we were expecting. The efficacy actually looks stronger than acondroplasia, and we have benefits beyond height straight out of the gate. So with arm span, as well as obviously you'd expect standing height, AGV, and Z-score.
Jun Li, Analyst — UBS
I was quite impressed that the annualized growth velocity in hypochondroplasia patients were actually better than the achondroplasia patients, because you would think that there's more room for growth in achon patients than in hypochondroplasia patients, but maybe hypochondroplasia patients respond better? What are thoughts there, or is it just within margin of error?
Alexander Hardy, CEO
No, no, no. We were expecting it was likely to be better. That's not how we parred. We parred the study for the same level of growth as achondroplasia, but we'd seen in the phase two that the DAOBA study, the growth rate was quite significant. I think this gets to the biology and the disease. It seems to be very amenable to CNP. That may not be the case with the other. Drugs that are coming, the FGFR3s, that's going to be a real question mark as to whether they're, and I know you also follow them, as to whether FGFR3s are going to be as effective in hypochondroplasia. It's interesting seeing their dose selection is going up or their dose is going up in their clinical study.
Jun Li, Analyst — UBS
Whether you want to be specific and targeted versus you bypass all that and then work downstream or upstream, there's a lot to say about, but that's why you do the experiments and you have good data. So congratulations. But so we have five minutes left and we got to talk about some pipeline because you have a lot going on. Why don't we start with BMN 333. It's a long acting version of Oxovo. This will be once a week. It'll be very competitive. It works. So tell us where you are with this very important program and what we should be expecting next year in terms of data disclosure.
Alexander Hardy, CEO
Yeah, I mean, this is very, very exciting. The potential, we believe, is to have a best-in-class treatment. And, you know, we're... We're optimistic with what we've seen. So we've seen a PK profile, which is really compelling. It also exceeded our expectations in the phase one study in healthy volunteers. We saw much, much higher PK levels than our target range versus our competitors' long-acting weekly formulation. So what we're doing is we've taken it, and the phase two is going extremely well in terms of recruitment, and we'll report out the results next year, is we've taken three of the dosages into a phase two, comparing head-to-head against Voxogo. And one of the dosages, for example, we achieved eight times. The free CNP levels, then I'll just say Ascendis is transcon CNP. So eight times the level of free CNP. We believe from preclinical models, we believe that there's a dose dependent effect. But this is the experiment. We'll see in patients what eight times the level of free CNP translates to in terms of annualized growth velocity. But we'll go straight then into a phase three. It's a seamless operational design. We'll drop right that into a head-to-head phase three study against Voxogo.
Jun Li, Analyst — UBS
Interesting point. You brought up a sentence. I'll talk about it. This is like a court case, isn't it? I entered it into the, okay, so it's free game. Go for it. Interesting, because FDA asked them to do, I guess, three or four component studies they were thinking of doing it, just a combination versus, you've developed versus. Placebo. The FDA asks them to do a human growth hormone alone to make sure that there's a synergy or additive effect. We'll see. I do think it's interesting because I think FDA do also have some questions as to whether they're actually additive for the FDA to ask them to do that human growth hormone alone arm. So we'll see what the data looks like.
Alexander Hardy, CEO
I think that's totally understandable. I mean, that's very predictable that the FDA would have that question. I mean, the FDA has considered growth hormone in achondroplasia and have turned it down up to this point. I would just say, I mean, you're sort of, now you've talked about it, so now I can talk about it. You started. I did start it. I don't think any of us are surprised that you see an additive benefit when you combine. That's really not the question that the clinical community and the patient community, is that effect going to be durable? You would expect growth hormone to have a short impact in terms of short. That's ironic. An impact on height over the short term, but is it going to translate to final adult height? I think you look at the data right now, and as it matures, it looks like the treatment effect is waning. Is the growth hormone causing the growth plates to close sooner? These are all questions that need to be answered. Let's wait for the data and see, but the data needs to speak.
Jun Li, Analyst — UBS
All right. We want to get through two more drugs quickly. We have two minutes left. The 440 is an oral drug for hypophosphatasia in which Strenzyk is doing, I guess, really well. Commercially, it's a daily injectable. You have a pill. Tell us about what we can expect in terms of data 1Q, I believe, 27 from the Phase 1-2 trial.
Alexander Hardy, CEO
Yeah, we're going to have data next year in 27. So this came from the Lester acquisition. So it's an oral treatment in a marketplace right now, which is really AstraZeneca, Strenzeek, and then they have their follow-on molecule, which is called 1850. I know you know this, but I'm saying it for the audience. But this is a lot more exciting than just an oral treatment. I mean, that is compelling in this sort of market. It's a very large market. Strenzyx sells about 1.7 billion a year. AstraZeneca has communicated that they believe that 1850 market potential is 3 to 5 billion. But by being the mechanism of action, it works in a different part of the pathway. The ERTs, the enzyme therapies, are bone targeting. We potentially will be able to reach the other morbidities, the muscle pain, muscle weakness associated with the disease. We think that's really, so this is much more exciting than just being an oral therapy. This could mean also that we get into the adult onset population, which it looks like 1850. I mean, they had a failed study there. We'll have to see what regulators do, but that bone pain, fatigue, is a much bigger issue in the adult onset population. We believe this drug has the profile to be able to do that. So, you know, important first data in patients next year. It's really exciting, but this could be a very big drug if it's successful.
Jun Li, Analyst — UBS
We actually have 10 minutes after this, so we can go over a couple more minutes to talk about 450, which I think is really exciting. It's a once weekly or once monthly The Sub-Q Auto Injector for Fabrice, for AllCommerce. Tell us about that program and your aspirations. Is it going to be competitive or canonizing your existing Fabrice program, or is it more synergistic?
Alexander Hardy, CEO
Yeah, so this is our most recent deal. This is hot off the press, a deal we did with two Korean companies. For what we call now BMN 450. So this potentially could be the first subcutaneous treatment for Febre's disease. So we talked about Febre at the beginning. That's where Gallifold is. This is exciting because it's, again, not just, you know, the first subcutaneous treatment, but Gallifold is limited to about 35 to 50% of patients that are amenable from a genetic standpoint. 4.50 will be able to address the whole market and have definitely a burden of treatment advantage over the current competitors. So it opens up the market for us considerably.
Jun Li, Analyst — UBS
You're already there, so why not? I think I've been covering you guys for a while, a prior firm as well as here, and I can tell you that sentiment has really improved in the last year. So I'm looking forward to your progress this year, and thank you for your time.